<DOC>
	<DOCNO>NCT02319577</DOCNO>
	<brief_summary>A sub-population patient affect non-small cell lung cancer ( NSCLC ) activate mutation epidermal growth factor receptor ( EGFR ) gain benefit treatment tyrosine-kinase inhibitor ( TKIs ) . The hypothesis study addition chemotherapy oral vinorelbine first-line TKI might result improved outcome EGFR-mutated patient .</brief_summary>
	<brief_title>GEfitinib Plus viNOrelbine Advanced EGFR Mutated NSCLC . GENOA Trial</brief_title>
	<detailed_description>In spite dramatic improvement obtain EGFR-TKIs patient affect NSCLC activate mutation EGFR , fraction patient ( 30 % ) respond EGFR-TKIs achieve response short duration . It suggest patient may affect additional mutation confer resistance EGFR-TKIs spite presence activate mutation EGFR gene . Pre-clinical study show addition chemotherapy gefitinib may result increased anti-proliferative activity , subsequent clinical study suggest synergic activity gefitinib chemotherapy depend employ schedule ( concurrent versus sequential ) . Additionally , data phase I trials gefitinib plus vinorelbine reveal high incidence severe hematological toxicity concurrent administration , sequential schedule result manageable safety profile . On basis aforementioned data , hypothesize sequential combination vinorelbine gefitinib might result improve outcome ( term response survival ) EGFR-mutated NSCLC gefitinib alone acceptable tolerability . The availability oral formulation vinorelbine make possible offer patient exclusively oral treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed informed consent At least 18 year old Histologically confirm NSCLC Stage IV disease Evidence activate mutation EGFR Measurable disease ( assessed RECIST 1.1 ) No previous chemotherapy biological therapy NSCLC Previous radiation treatment allow , unless eligible target lesion irradiate , provide least 2 week pass end radiation therapy start treatment study Eastern Cooperative Oncology Group ( ECOG ) performance status : 01 Adequate baseline bone marrow , hepatic renal function In presence central nervous system metastasis , patient asymptomatic least 4 week start treatment study Patients receive neoadjuvant adjuvant chemotherapy , concurrent chemoradiation nonmetastatic , radically treat NSCLC consider eligible , provide receive vinorelbine part treatment Female patient must provide negative pregnancy test ( serum urine ) prior treatment Other malignancy within last 3 year , exclusion nonmelanoma skin neoplasm insitu carcinoma cervix Grade IIIIV New York Heart Association ( HYHA ) cardiac dysfunction Acute myocardial infarction pulmonary embolism last 6 month Brain metastasis meningeal carcinomatosis spinal cord compression , unless control asymptomatic least 30 day start study treatment HIV positivity AIDS require pharmacological treatment Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>gefitinib</keyword>
</DOC>